Increased visceral adipocyte lipolysis--a pathogenic role in nonalcoholic fatty liver disease?
The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
CONTEXT: Obesity is a major risk factor for nonalcoholic fatty liver disease, but the primary pathophysiological mechanisms remain unclear. OBJECTIVE: The aim was to study the relative role of visceral and sc in vitro lipolysis for liver fat accumulation. PATIENTS: Eighteen morbidly obese women participated in the study. DESIGN: Hepatic triglyceride accumulation and abdominal visceral and sc fat area were assessed by computer tomography. Biopsies were taken from abdominal sc and visceral fat tissue. Basal and maximal lipolysis was measured using various lipolytic drugs acting at different steps in the lipolytic cascade. RESULTS: No difference in total body, visceral, or sc fat mass was found between patients with high, intermediate, or low amounts of liver fat. In patients with high liver fat content, there was an approximately 2-fold increase in visceral adipocyte maximal glycerol release induced by the different lipolytic agents (P = 0.002 to 0.01). Noradrenaline-mediated free fatty acid release from visceral adipocytes was also about twice as high in patients with high liver fat (P = 0.004). In contrast, in sc adipocytes, no relationship between liver fat content and either glycerol or free fatty acid release was found. CONCLUSIONS: We suggest a pathogenic role of visceral, but not sc, adipocyte lipolytic function in nonalcoholic fatty liver disease, independent of total body fat as well as abdominal fat distribution.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“VAT is increased with intrahepatic triglycerides (IHTGs) even in individuals without obesity,11 and is associated with IR11,16.”
From Lipid metabolism in MASLD and MASH: From mechanism to the clinic (2024) · cites this paper as [16]
Citations
Cites
Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985) · Diabetologia · doi:10.1007/bf00280883 · Cited by 31,502 · cited 1×
“Insulin sensitivity was calculated from the homeostasis model assessment (HOMA) algorithm (12).”
MethodDonnelly, K. L., Smith, C. I., Schwarzenberg, S. J., Jessurun, J., Boldt, M. D., & Parks, E. J. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23621 · Cited by 3,604 · cited 13×
“The effect of noradrenaline on visceral fat FFA release was also about twice as high in patients with high liver fat accumulation.”
BackgroundInfluentialHow Useful Is Body Mass Index for Comparison of Body Fatness across Age, Sex, and Ethnic Groups?
Gallagher, D., Visser, M., Sepulveda, D., Pierson, R. N., Harris, T., & Heymsfield, S. B. (1996) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a008733 · Cited by 1,513
Prediction of Non-Alcoholic Fatty Liver Disease and Liver Fat Using Metabolic and Genetic Factors
Kotronen, A., Peltonen, M., Hakkarainen, A., Sevastianova, K., Bergholm, R., Johansson, L. M., Lundbom, N., Rissanen, A., Ridderstråle, M., Groop, L., et al. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.06.005 · Cited by 804 · cited 11×
“Downloaded from https://academic.oup.com/jcem/article-abstract/95/10/E209/2835355 by guest on 30 July 2018 but not cell surface adrenoceptor-mediated processes, are involved in visceral adipocyte lipolysis activation of female obese patients with NAFLD.”
MethodInfluentialSchwenzer, N. F., Springer, F., Schraml, C., Stefan, N., Machann, J., & Schick, F. (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2009.05.023 · Cited by 749 · cited 2×
“These HU figures are in agreement with defining a high predictability of hepatic steatosis by HU values below 40 and healthy liver by HU above 50 (16).”
MethodResultFabbrini, E., Mohammed, B. S., Magkos, F., Korenblat, K. M., Patterson, B. W., & Klein, S. (2008) · Gastroenterology · doi:10.1053/j.gastro.2007.11.038 · Cited by 631
Visceral fat: A key mediator of steatohepatitis in metabolic liver disease†
van der Poorten, D., Milner, K., Hui, J., Hodge, A., Trenell, M. I., Kench, J. G., London, R., Peduto, T., Chisholm, D. J., & George, J. (2008) · Hepatology · doi:10.1002/hep.22350 · Cited by 607 · cited 4×
“(J Clin Endocrinol Metab 95: E209–E213, 2010) Nonalcoholic fatty liver disease (NAFLD) is a condi-tion characterized by a wide spectrum of hepatic lesions ranging from uncomplicated steatosis via inflammation [nonalcoholic steatohepatitis (NASH)] to fibrosis and cirrhosis (1).”
BackgroundInfluentialAbdominal Subcutaneous Adipose Tissue: A Protective Fat Depot?
Porter, S. A., Massaro, J. M., Hoffmann, U., Vasan, R. S., O'Donnel, C. J., & Fox, C. S. (2009) · Diabetes Care · doi:10.2337/dc08-2280 · Cited by 487
Thörne, A., Lönnqvist, F., Apelman, J., Hellers, G., & Arner, P. (2002) · International Journal of Obesity · doi:10.1038/sj.ijo.0801871 · Cited by 463 · cited 1×
“We have previously shown that the in vitro release of FFA from visceral adipocytes is indeed increased in obesity (15) and also that visceral fat reduction (omentectomy) in connection with bariatric surgeryhaspositiveand long-termeffectsonglucoseand insulin metabolic profiles in obese patients (19).”
BackgroundSelf-citationHuman fat cell lipolysis: biochemistry, regulation and clinical role.
Arner, P. (2005) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2005.07.004 · Cited by 401 · cited 3×
“Also, peripheral plasma levels of FFAs, which above all originate from sc adipocyte lipolysis (18), did not differ between patients with high or low liver fat accumulation.”
BackgroundInfluential
Cited by
The Subtle Balance between Lipolysis and Lipogenesis: A Critical Point in Metabolic Homeostasis
Saponaro, C., Gaggini, M., Carli, F., & Gastaldelli, A. (2015) · Nutrients · doi:10.3390/nu7115475 · Cited by 529
“Sweet death”: Fructose as a metabolic toxin that targets the gut-liver axis
Febbraio, M. A., & Karin, M. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2021.09.004 · Cited by 173
Lipid metabolism in MASLD and MASH: From mechanism to the clinic
Carli, F., Della Pepa, G., Sabatini, S., Vidal Puig, A., & Gastaldelli, A. (2024) · JHEP Reports · doi:10.1016/j.jhepr.2024.101185 · Cited by 147
“14,15 VAT is increased with intra-hepatic triglycerides (IHTGs) even in individuals without obesity, 11 and is associated with IR 11,16 .”
Nati, M., Haddad, D., Birkenfeld, A. L., Koch, C. A., Chavakis, T., & Chatzigeorgiou, A. (2016) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-016-9339-2 · Cited by 147
“free fatty acid supply in the liver [9].”
BackgroundVariations in the Size of the Major Omentum Are Primarily Determined by Fat Cell Number
Arner, P., Andersson, D. P., Thörne, A., Wirén, M., Hoffstedt, J., Näslund, E., Thorell, A., & Rydén, M. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-4106 · Cited by 102
“The ratio between visceral and total (ie, visceral and sc) area was determined as described previously (11-13) and in the Supplemental Materials and Methods (published on The Endocrine Society’s Journals Online web site at http://jcem.”
BackgroundSelf-citationZhao, P., & Saltiel, A. R. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.rev120.011356 · Cited by 109
“Enhanced lipolysis in adipose tissue increases circulating fatty acids, which in turn leads to hepatic fatty acid uptake and promotes steatosis (74, 75).”
BackgroundMesenteric Fat Lipolysis Mediates Obesity-Associated Hepatic Steatosis and Insulin Resistance
Wueest, S., Item, F., Lucchini, F. C., Challa, T. D., Müller, W., Blüher, M., & Konrad, D. (2016) · Diabetes · doi:10.2337/db15-0941 · Cited by 96
“Moreover, increased omental but not subcutaneous lipolysis was linked to obesityinduced fatty liver disease in humans with morbid obesity (44).”
BackgroundEicosanoids in Metabolic Syndrome
Hardwick, J. P., Eckman, K., Lee, Y., Abdelmegeed, M. A., Esterle, A. R., Chilian, W. M., Chiang, J. Y. L., & Song, B. (2013) · Advances in pharmacology · doi:10.1016/b978-0-12-404717-4.00005-6 · Cited by 107
“Furthermore, VAT release of FFA is twofold higher than in SAT in humans with NAFLD suggesting a pathological role of VAT, but not SAT adipocyte lipolytic, function in MetS (Thorne et al., 2010).”
BackgroundThe pathophysiology of abdominal adipose tissue depots in health and disease
Walker, G. E., Marzullo, P., Ricotti, R., Bona, G., & Prodam, F. (2014) · Hormone Molecular Biology and Clinical Investigation · doi:10.1515/hmbci-2014-0023 · Cited by 90
“Further, a pathogenic role for VAT adipocyte lipolytic function in NAFLD, independent of total body fat as well as abdominal fat distribution, has been observed in morbidly obese women, emphasizing further the key role VAT lipolytic activity [109].”
BackgroundGlucocorticoid activation of anti-inflammatory macrophages protects against insulin resistance
Caratti, G., Stifel, U., Caratti, B., Jamil, A. J. M., Chung, K.-J., Kiehntopf, M., Gräler, M. H., Blüher, M., Rauch, A., & Tuckermann, J. P. (2023) · Nature Communications · doi:10.1038/s41467-023-37831-z · Cited by 48
Brumbaugh, D. E., Crume, T., Nadeau, K. J., Scherzinger, A. L., & Dabelea, D. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-3243 · Cited by 46
“Visceral adipocytes, when compared in vitro to sc adipocytes, have also been shown to be more proinflammatory and lipolytic (9, 10).”
BackgroundMichaliszyn, S. F., Lee, S., Tfayli, H. M., & Arslanian, S. A. (2013) · Fertility and Sterility · doi:10.1016/j.fertnstert.2013.08.015 · Cited by 46
“In 18 morbidly obese women with high liver fat content, there was a 2-fold increase in visceral adipocyte derived glycerol release (50).”
BackgroundLim, S.-M., Kim, E., Shin, J.-H., Seok, P. R., Jung, S., Yoo, S., & Kim, Y. (2018) · Molecules · doi:10.3390/molecules23030705 · Cited by 32
Kim, K. H., Oh, S., Kwon, H., Park, J., Choi, H.-C., & Cho, B. (2012) · Annals of Nutrition and Metabolism · doi:10.1159/000334710 · Cited by 36
Vanillic Acid and Non-Alcoholic Fatty Liver Disease: A Focus on AMPK in Adipose and Liver Tissues
Shekari, S., Khonsha, F., Rahmati‐Yamchi, M., Nejabati, H. R., & Mota, A. (2021) · Current Pharmaceutical Design · doi:10.2174/1381612827666210701145438 · Cited by 25
A short bout of HFD promotes long-lasting hepatic lipid accumulation
Chiazza, F., Challa, T. D., Lucchini, F. C., Konrad, D., & Wueest, S. (2015) · Adipocyte · doi:10.1080/21623945.2015.1071454 · Cited by 19
“In support of such notion, increased visceral lipolysis was linked to obesity-induced fat accumulation in morbidly obese humans.(10) The negative impact of short-term high fat feeding on glucose metabolism and liver fat accumulation is well”
BackgroundCoêlho, C. F. F., França, L. M., do Nascimento, J. R., dos Santos, A. M., Azevedo-Santos, A. P. S., do Nascimento, F. R. F., & Paes, A. M. D. A. (2018) · Journal of Developmental Origins of Health and Disease · doi:10.1017/s2040174418000284 · Cited by 14
Maciejewska, D., Palma, J., Dec, K., Skonieczna‐Żydecka, K., Gutowska, I., Szczuko, M., Jakubczyk, K., & Stachowska, E. (2019) · Diagnostics · doi:10.3390/diagnostics9040197 · Cited by 14
Kim, D., Cholankeril, G. T., & Ahmed, A. (2024) · Journal of Obesity & Metabolic Syndrome · doi:10.7570/jomes24005 · Cited by 13
Metabolic drivers of MASLD and MASH: from hormonal imbalance to fibrosis
Gastaldelli, A., Scoditti, E., & Macedo, M. P. (2026) · Diabetologia · doi:10.1007/s00125-026-06774-7 · Cited by 12
“Consistent associations between VAT and hepatic steatosis support a key role for VAT in disease pathogenesis, although causality independent of whole-body metabolic dysfunction remains unproven [10, 12, 15, 17].”
Fibroblast growth factor 21 decreases after liver fat reduction via growth hormone augmentation
Braun, L. R., Feldpausch, M. N., Czerwonka, N., Torriani, M., Grinspoon, S. K., & Stanley, T. L. (2017) · Growth Hormone & IGF Research · doi:10.1016/j.ghir.2017.10.002 · Cited by 10
Štofková, A., Kršková, K., Vaculín, Š., & Jur̀čovičová, J. (2016) · Autoimmunity · doi:10.3109/08916934.2016.1164145 · Cited by 7
“In support of this notion, a higher lipolytic activity of abdominal visceral WAT (localized in close proximity to mesenteric lymph nodes), but not subcutaneous WAT (nodeless adipose depot) has been found to be crucial for the development of hepatic steatosis and cardiovascular disease in humans [15,16].”
BackgroundDepot-specific metabolic and inflammatory profiles in perirenal and renal sinus adipose tissue
Pereira, M. J., Mathioudaki, A., Hetty, S., Sedigh, A., Eriksson, J. W., & Svensson, M. K. E. (2025) · Molecular Medicine · doi:10.1186/s10020-025-01323-1 · Cited by 5
“This aligns with OATs important role in metabolic regulation, particularly in lipolysis and stress response [32, 33].”
Chen, J., Jin, B., Wang, F., Wu, Z., Dorazio, R. M., & Fu, J. (2023) · European Journal of Clinical Nutrition · doi:10.1038/s41430-023-01326-3 · Cited by 1
“Our fi ndings warrant more investigation to determine the association between gynoid fat and NAFLD and suggest that reducing fat mass and increasing lean mass may be helpful in combatting NAFLD.”
BackgroundNonalcoholic fatty liver disease: What comes before and what are the consequences?
Bril, F. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-88426-6.00017-8
Metadata
- Authors
- Thörne, A., Löfgren, P., & Hoffstedt, J.
- Affiliations
- Karolinska Institutet (SE)
- Karolinska University Hospital (SE)
- Corresponding author
- Hoffstedt, Johan
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2010-10
- Volume
- 95
- Issue
- 10
- Pages
- E209-E213
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2094526525
- Cited by
- 25
- References
- 20
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 3 · 2023: 2 · 2021: 2 · 2020: 1 · 2019: 1 · 2018: 2 · 2017: 1 · 2016: 2 · 2015: 3 · 2014: 1 · 2013: 3 · 2012: 2
- FWCI
- 1.16
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Lipid metabolism and biosynthesis
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Disease and Adiposity
- Keywords
- non-alcoholic fatty liver disease, visceral adipose tissue, subcutaneous adipose tissue, adipocyte lipolysis, hepatic triglyceride accumulation, obesity, norepinephrine, free fatty acid release, glycerol release, morbid obesity, abdominal fat distribution
- MeSH terms
- Adult, Fatty Liver, Female, Humans, Lipolysis, Middle Aged, Norepinephrine, Obesity, Morbid, Up-Regulation, Adipocytes, Biopsy, Fine-Needle, Subcutaneous Fat, Intra-Abdominal Fat, Body Fat Distribution, Young Adult, In Vitro Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.